http://www.gbipharma.com en-us ℗ & © 2007 GBIpharma.com China's pharma & biotech industries are vibrant, exciting, and expanding rapidly. This podcast series reveals the real story on the ground and engages with the people shaping the landscape. GB Information China's pharma & biotech industries are vibrant, exciting, and expanding rapidly. This podcast series reveals the real story on the ground and engages with the people shaping the landscape. China's pharma & biotech industries are vibrant, exciting, and expanding rapidly. This podcast series reveals the real story on the ground and engages with the people shaping the landscape. GB Podcast podcast@generalbiologic.com Generalbiologic This month, Senior Director of Personalized Healthcare Market Development at QIAGEN, Andrew Webb, sits down with GBI to discuss the exciting field of personalized medicine. In this interview, Andrew offers an insider look at new applications for molecular targeting, as well as the role this technology will play in pharmaceutical development in the future. This month, Senior Director of Personalized Healthcare Market Development at QIAGEN, Andrew Webb, sits down with GBI to discuss the exciting field of personalized medicine. In this interview, Andrew offers an insider look at new applications for molecular targeting, as well as the role this technology will play in pharmaceutical development in the future. http://www.gbipharma.com/podcast/mp3/GBI_Andrew_webb_interview.mp3 Wed, 30 Jun 2010 08:30:27 +0000 41.55 Generalbiologic Generalbiologic GBI sat down with Andreas Amrein, Head of Marketing and Sales Operations for Novartis China, to talk about pharmaceutical commercial sales and promotion-including a comparison of strategies and tactics used here to those in Western markets. Andreas also shares his opinions on medical rep-doctor relations, hospital listings, and the challenges of product launches in China. GBI sat down with Andreas Amrein, Head of Marketing and Sales Operations for Novartis China, to talk about pharmaceutical commercial sales and promotion-including a comparison of strategies and tactics used here to those in Western markets. Andreas also shares his opinions on medical rep-doctor relations, hospital listings, and the challenges of product launches in China. http://www.gbipharma.com/podcast/mp3/GBI_andreas_interview.mp3 Thu, 15 Apr 2010 08:39:20 +0000 48.05 Generalbiologic Generalbiologic John Oyler, founder of recently acquired life science CRO, BioDuro, sits down to discuss the motivation and process behind establishing and growing BioDuro, shares an insider’s view of where the CRO industry as a whole is headed, and his future plans. John also offers advice to future would-be entrepreneurs on what it takes to be successful in China and beyond. John Oyler, founder of recently acquired life science CRO, BioDuro, sits down to discuss the motivation and process behind establishing and growing BioDuro, shares an insider’s view of where the CRO industry as a whole is headed, and his future plans. John also offers advice to future would-be entrepreneurs on what it takes to be successful in China and beyond. http://www.gbipharma.com/podcast/mp3/GBI_John_Oyler_interview.mp3 Thu, 15 Apr 2010 08:39:20 +0000 48.09 Generalbiologic Generalbiologic Interview with David Pieroni, Managing Director of Automation Quality Solutions (AQS). In this interview David discusses the different GXP regimes in China and overseas and challenges regarding quality assurance and compliance in China. David touches on the CRO, pharmaceutical, API, and device industries, and what to expect in the QA/QC area in China moving forward. Interview with David Pieroni, Managing Director of Automation Quality Solutions (AQS). In this interview David discusses the different GXP regimes in China and overseas and challenges regarding quality assurance and compliance in China. David touches on the CRO, pharmaceutical, API, and device industries, and what to expect in the QA/QC area in China moving forward. http://www.gbipharma.com/podcast/mp3/GBI David Pieroni interview.mp3 Thu, 14 Jan 2010 10:09:56 +0000 27.46 Generalbiologic Generalbiologic This month, GBI sits down with Dr. Sean Hu, the CEO and Chairman of Beike Biotechnology. In this interview, Dr. Hu discusses the motivation behind his commitment to stem-cell research as well as Beike's current research and clinical application status. He offers a detailed outline of Beike's business model and its future plans as the frontrunner in this up and coming industry. This month, GBI sits down with Dr. Sean Hu, the CEO and Chairman of Beike Biotechnology. In this interview, Dr. Hu discusses the motivation behind his commitment to stem-cell research as well as Beike's current research and clinical application status. He offers a detailed outline of Beike's business model and its future plans as the frontrunner in this up and coming industry. http://www.gbipharma.com/podcast/mp3/GBI Sean Hu interview.mp3 Tue, 01 Dec 2009 01:51:02 +0000 30.07 Generalbiologic Generalbiologic In this interview IP experts Mark Cohen and Tony Chen shared their deep cumulative experiences from both the policy and practice perspective. In addition to broad patent and trademark issues, Mark and Tony explained the inventor's rights portions of the new patent law, explain the use of China to avoid platform technology patents, and discussed the outlook and forces for change in China's IP regime. In this interview IP experts Mark Cohen and Tony Chen shared their deep cumulative experiences from both the policy and practice perspective. In addition to broad patent and trademark issues, Mark and Tony explained the inventor's rights portions of the new patent law, explain the use of China to avoid platform technology patents, and discussed the outlook and forces for change in China's IP regime. http://www.gbipharma.com/podcast/mp3/GBI Mark and Tony interview.mp3 Fri, 30 Oct 2009 01:57:12 +0000 53.35 Generalbiologic Generalbiologic In this interview, Philip Xiao, the co-founder and CDO of Profex Inc, discusses such topics as Profex's struggle to grow from a small startup into a major player in China's dermatology market, the unique challenges facing Profex, anticipated effects of the new medical reform, and the company's future plans. In this interview, Philip Xiao, the co-founder and CDO of Profex Inc, discusses such topics as Profex's struggle to grow from a small startup into a major player in China's dermatology market, the unique challenges facing Profex, anticipated effects of the new medical reform, and the company's future plans. http://www.gbipharma.com/podcast/mp3/GBI Philip Xiao Interview.mp3 Wed, 23 Sep 2009 01:12:30 +0000 31.46 Generalbiologic Generalbiologic In this interview, Victor enlightens us on Qiagen's China products and services, the possible impact of the nation's healthcare reform on the molecular diagnostics sector, and the competitive landscape in Qiagen's business segments. Victor also addresses the company’s strategic plan for Asia as well as its past China acquisitions and the challenges associated with integrating those businesses. In this interview, Victor enlightens us on Qiagen's China products and services, the possible impact of the nation's healthcare reform on the molecular diagnostics sector, and the competitive landscape in Qiagen's business segments. Victor also addresses the company’s strategic plan for Asia as well as its past China acquisitions and the challenges associated with integrating those businesses. http://www.gbipharma.com/podcast/mp3/GBI Victor Shi interview.mp3 Fri, 28 Aug 2009 08:10:08 +0000 41.17 Generalbiologic Generalbiologic Interview with Sheldon Dorenfest, CEO of the Dorenfest Group, an investment and consulting firm focused on health care systems improvement. In this interview, Sheldon, an internationally recognized authority on healthcare I.T., expands on the positives and negatives of the Chinese healthcare system, the status of I.T. in healthcare institutions, and the I.T. resources currently needed by the nation’s physicians. Sheldon also discusses the entry of multinational I.T. providers, such as IBM and Microsoft, to the H.I.T. market and regulatory roadblocks to future progression of the sector. Interview with Sheldon Dorenfest, CEO of the Dorenfest Group, an investment and consulting firm focused on health care systems improvement. In this interview, Sheldon, an internationally recognized authority on healthcare I.T., expands on the positives and negatives of the Chinese healthcare system, the status of I.T. in healthcare institutions, and the I.T. resources currently needed by the nation’s physicians. Sheldon also discusses the entry of multinational I.T. providers, such as IBM and Microsoft, to the H.I.T. market and regulatory roadblocks to future progression of the sector. http://www.gbipharma.com/podcast/mp3/GBI Sheldon I. Dorenfest interview.mp3 Wed, 24 Jun 2009 06:30:25 +0000 32.42 Generalbiologic Generalbiologic Interview with Ben Avancena, General Manager of Johnson & Johnson Medical (China) and international vice president for Johnson & Johnson's medical diagnostics division. In this interview, Ben discusses the highlights and challenges of being the GM of a multinational medical device company in China, the impact of the new healthcare reforms on the medical device and diagnostics sector, and strategies for multinational and domestic medical device companies going forward in China. Interview with Ben Avancena, General Manager of Johnson & Johnson Medical (China) and international vice president for Johnson & Johnson's medical diagnostics division. In this interview, Ben discusses the highlights and challenges of being the GM of a multinational medical device company in China, the impact of the new healthcare reforms on the medical device and diagnostics sector, and strategies for multinational and domestic medical device companies going forward in China. http://www.gbipharma.com/podcast/mp3/GBI Ben interview.mp3 Wed, 24 Jun 2009 06:29:56 +0000 32.14 Generalbiologic Generalbiologic Interview with Carl Firth, Head of Asia Healthcare at Bank of America-Merrill Lynch. Carl analyzes China's deal landscape for healthcare, the current investor environment, M&A appetites of both multinationals and domestics, and gives his observations of changes in the sector that have occurred over the past 12 to 18 months. Interview with Carl Firth, Head of Asia Healthcare at Bank of America-Merrill Lynch. Carl analyzes China's deal landscape for healthcare, the current investor environment, M&A appetites of both multinationals and domestics, and gives his observations of changes in the sector that have occurred over the past 12 to 18 months. http://www.gbipharma.com/podcast/mp3/GBI Carl Firth interview.mp3 Thu, 21 May 2009 06:14:04 +0000 41.87 Generalbiologic Generalbiologic Interview with Arthur C. Mok, resident partner at Hogan & Hartson's Shanghai office. In this interview, Arthur shares his insights on the current deal environment in China's healthcare industry. He discusses the impact of the global economic crisis on investment and important covenants in acquisition and licensing deals in China. Interview with Arthur C. Mok, partner at Hogan & Hartson's Shanghai office. In this interview, Arthur shares his insights on the current deal environment in China's healthcare industry. He discusses the impact of the global economic crisis on investment and important covenants in acquisition and licensing deals in China. http://www.gbipharma.com/podcast/mp3/GBI Mok Interview.mp3 Thu, 19 Mar 2009 05:39:49 +0000 37.67 Generalbiologic Generalbiologic Interview with Dr. Jonathan Seah, former CEO of ParkwayHealth China. ParkwayHealth is one of the largest providers of private healthcare in Asia and China. In this interview, Jonathan discusses Parkway's strategy and approach in the mainland; the impact of the new medical reforms; and the past, present, and future of private healthcare in China. He also shares his plans for his latest venture. Interview with Dr. Jonathan Seah, former CEO of ParkwayHealth China. ParkwayHealth is one of the largest providers of private healthcare in Asia and China. In this interview, Jonathan discusses Parkway's strategy and approach in the mainland; the impact of the new medical reforms; and the past, present, and future of private healthcare in China. He also shares his plans for his latest venture. http://www.gbipharma.com/podcast/mp3/GBI Jonathan Seah Interview.mp3 Mon, 02 Feb 2009 01:49:36 +0000 48.42 Generalbiologic Generalbiologic In this interview, Reto outlines his experience with Schwarz Pharma, his drive to create and expand RxMidas, and the key role of product sourcing strategies in to specialty pharmaceutical companies. Reto also touches on medical reform, his experience with distribution, the company’s focus on CNS and cardiovascular disease, and his vision for the company. In this interview, Reto outlines his experience with Schwarz Pharma, his drive to create and expand RxMidas, and the key role of product sourcing strategies in to specialty pharmaceutical companies. Reto also touches on medical reform, his experience with distribution, the company’s focus on CNS and cardiovascular disease, and his vision for the company. http://www.gbipharma.com/podcast/mp3/GBI Reto Rietmann Interview.mp3 Tue, 16 Dec 2008 01:09:17 +0000 31.51 Generalbiologic Generalbiologic In this interview Eric reflects on his 20 year experience in China, the development of the distribution industry and Zuellig's special role in the value chain. Eric shares his thoughts on M&A, consolidation, vertical integration, and the future of distribution in China's rapidly changing landscape. In this interview Eric reflects on his 20 year experience in China, the development of the distribution industry and Zuellig's special role in the value chain. Eric shares his thoughts on M&A, consolidation, vertical integration, and the future of distribution in China's rapidly changing landscape. http://www.gbipharma.com/podcast/mp3/GBI Eric Zwisler Interview.mp3 Thu, 13 Nov 2008 01:09:17 +0000 38.50 Generalbiologic Generalbiologic Interview with Dr. Allan Liu, Director of Business Development for Fosun Pharma, a major publicly listed domestic pharmaceutical company with business lines spanning therapeutics, diagnostics, and retail pharmacy. In this interview Allan discusses how Fosun uncovers business opportunities, and the company's areas of interest for licensing. He also gives an overview of the challenges facing the domestic pharmaceutical industry, including the struggle to develop in-house innovative R&D capabilities. Interview with Dr. Allan Liu, Director of Business Development for Fosun Pharma, a major publicly listed domestic pharmaceutical company with business lines spanning therapeutics, diagnostics, and retail pharmacy. In this interview Allan discusses how Fosun uncovers business opportunities, and the company's areas of interest for licensing. He also gives an overview of the challenges facing the domestic pharmaceutical industry, including the struggle to develop in-house innovative R&D capabilities. http://www.gbipharma.com/podcast/mp3/GBI Allan Liu Interview.mp3 Wed, 12 Nov 2008 01:09:17 +0000 37.47 Generalbiologic Generalbiologic In this interview, YuWen discusses the progress BioBay has made in attracting companies, the status of its venture fund, the competitive landscape for biotech zones, and the challenges such zones face in developing the industry. She highlighted the park’s progresses and how she measures success. In this interview, YuWen discusses the progress BioBay has made in attracting companies, the status of its venture fund, the competitive landscape for biotech zones, and the challenges such zones face in developing the industry. She highlighted the park’s progresses and how she measures success. http://www.gbipharma.com/podcast/mp3/GBI Yuwen Liu Interview.mp3 Mon, 22 Sep 2008 01:09:17 +0000 37.47 Generalbiologic Generalbiologic In this interview, Dave provided practical and strategic advice to pharmaceutical companies, especially those focused on China’s growing cancer market. He highlighted execution, pricing, and reimbursement issues and illuminated the importance of key hospitals and biologics. In this interview, Dave provided practical and strategic advice to pharmaceutical companies, especially those focused on China’s growing cancer market. He highlighted execution, pricing, and reimbursement issues and illuminated the importance of key hospitals and biologics. http://www.gbipharma.com/podcast/mp3/GBI Mark Engel Interview.mp3 Mon, 22 Sep 2008 01:09:17 +0000 39.57 Generalbiologic Generalbiologic In this interview, Mark discusses how he founded and grew Excel Pharmastudies into one of the leading CRO's in China. Mark also addressed opportunities and challenges for big pharma and biotech looking to conduct clinical trials in China. He specifically touches on chemical vs. biologic products, and the rapidly changing competitive landscape for clinical trials providers in China. In this interview, Mark discusses how he founded and grew Excel Pharmastudies into one of the leading CRO's in China. Mark also addressed opportunities and challenges for big pharma and biotech looking to conduct clinical trials in China. He specifically touches on chemical vs. biologic products, and the rapidly changing competitive landscape for clinical trials providers in China. http://www.gbipharma.com/podcast/mp3/GBI Mark Engel Interview.mp3 Mon, 28 Jul 2008 01:09:17 +0000 47.20 Generalbiologic Generalbiologic Hutchison Medipharma is Shanghai-based pioneer in new drug discovery. In this interview, Samantha discusses the genesis of Medipharma, the company's leading products, progress in clinical trials, high profile deals with Lilly and others, and the current corporate structure. Samantha also elaborates on the company's patent estate and how Medipharma protects its small molecule, mixture, and extract candidates. Hutchison Medipharma is Shanghai-based pioneer in new drug discovery. In this interview, Samantha discusses the genesis of Medipharma, the company's leading products, progress in clinical trials, high profile deals with Lilly and others, and the current corporate structure. Samantha also elaborates on the company's patent estate and how Medipharma protects its small molecule, mixture, and extract candidates. http://www.gbipharma.com/podcast/mp3/GBI Samantha Du Interview.mp3 Wed, 28 May 2008 09:37:08 +0000 38.58 Generalbiologic Generalbiologic This month GBI talked with Peter Zhang, CEO of GenePharma. GenePharma is a leading company in China's RNA industry. Peter touched the process of starting a biotech in China, challenges in financing and reaching overseas markets, and the state of China's RNA research. He also explained the reasons for the company’s move to Suzhou’s nascent BioBay from Shanghai's ZhangJiang high technology park. This month GBI talked with Peter Zhang, CEO of GenePharma. GenePharma is a leading company in China's RNA industry. Peter touched the process of starting a biotech in China, challenges in financing and reaching overseas markets, and the state of China's RNA research. He also explained the reasons for the company’s move to Suzhou’s nascent BioBay from Shanghai's ZhangJiang high technology park. http://www.gbipharma.com/podcast/mp3/GBI Peter Zhang Interview.mp3 Wed, 30 Apr 2008 09:31:08 +0000 34.33 Generalbiologic Generalbiologic This month GBI talked XianPing Lu, co-founder and president of Chipscreen Biosciences. Based in Shenzhen, Chipscreen is one of China's true drug discovery pioneers, having developed a platform technology and successfully driving several drug candidates into preclinical and clinical testing. In this interview, Dr. Lu discusses the founding of the company, its expanding pipeline, and the value of partnering with multinationals. He also touches on Chipscreen's plans for an IPO on China’s nascent NASDAQ-like board and strategy for commercialization of its late stage candidates. This month GBI talked XianPing Lu, co-founder and president of Chipscreen Biosciences. Based in Shenzhen, Chipscreen is one of China's true drug discovery pioneers, having developed a platform technology and successfully driving several drug candidates into preclinical and clinical testing. In this interview, Dr. Lu discusses the founding of the company, its expanding pipeline, and the value of partnering with multinationals. He also touches on Chipscreen's plans for an IPO on China’s nascent NASDAQ-like board and strategy for commercialization of its late stage candidates. http://www.gbipharma.com/podcast/mp3/GBI Peter Zhang Interview.mp3 Tue, 29 Apr 2008 08:21:08 +0000 37.49 Generalbiologic Generalbiologic This month, GBI sat down with Jing Lou, the CEO of 3SBio, a Chinese biopharmaceutical company that conducted an IPO on NASDAQ in February of 2007. In this interview, Dr. Lou discussed the company's leading product, a generic EPO, and the status of its other products and candidates. Dr. Lou discussed his plans for 3SBio's IPO cash, the impact of recent regulatory changes on the company's market share and prospects, and expanded on the potential for generic biologics in the European and United States markets. This month, GBI sat down with Jing Lou, the CEO of 3SBio, a Chinese biopharmaceutical company that conducted an IPO on NASDAQ in February of 2007. In this interview, Dr. Lou discussed the company's leading product, a generic EPO, and the status of its other products and candidates. Dr. Lou discussed his plans for 3SBio's IPO cash, the impact of recent regulatory changes on the company's market share and prospects, and expanded on the potential for generic biologics in the European and United States markets. http://www.gbipharma.com/podcast/mp3/GBI Jing Luo Interview.mp3 Thu, 31 Jan 2008 03:17:10 +0000 31.01 Generalbiologic Generalbiologic James Wen, CEO of SynCores, an emerging chemical synthesis service provider, discusses his views on industry growth in China, the evolution of the R&D services business model, the impact of rising wages and RMB pressure, and how to move from success based projects to an FTE model. James Wen, CEO of SynCores, an emerging chemical synthesis service provider, discusses his views on industry growth in China, the evolution of the R&D services business model, the impact of rising wages and RMB pressure, and how to move from success based projects to an FTE model. http://www.gbipharma.com/podcast/mp3/GBI James Wen Interview.mp3 Tue, 22 Jan 2008 07:54:58 +0000 26.53 Generalbiologic Generalbiologic Patrice Bonzom, General Manager of Crucell in China, discusses China's vaccine industry. Covered in this interview is Crucell's growing presence, thoughts on the market for subsidized and unsubsidized vaccines, the potential of the influenza vaccine market, China's pandemic preparations, and multinationals' options for domestic manufacturing. Patrice Bonzom, General Manager of Crucell in China, discusses China's vaccine industry. Covered in this interview is Crucell's growing presence, thoughts on the market for subsidized and unsubsidized vaccines, the potential of the influenza vaccine market, China's pandemic preparations, and multinationals' options for domestic manufacturing. http://www.gbipharma.com/podcast/mp3/GBI Patrice Bonzom Interview.mp3 TUE, 11 Dec 2007 09:11:27 +0000 29.50 Generalbiologic Generalbiologic Kabir Nath, President of Bristol Myers Squibb in China, expands upon the roles of a GM of a multinational pharma in China and discusses BMS's success with Baraclude. Kabir also shares his thoughts on China's pricing process and discusses big pharma's growth constraints in China's rapidly expanding pharmaceutical market. Kabir Nath, President of Bristol Myers Squibb in China, expands upon the roles of a GM of a multinational pharma in China and discusses BMS's success with Baraclude. Kabir also shares his thoughts on China's pricing process and discusses big pharma's growth constraints in China's rapidly expanding pharmaceutical market. http://www.gbipharma.com/podcast/mp3/GBI Kabir Nath Interview.mp3 Mon, 05 Nov 2007 09:11:27 +0000 33.51 Generalbiologic Generalbiologic In this interview, Mark Lotter, founder and CEO of NovaMed, shares his experience transitioning from big pharma to a start-up, specialty pharmaceutical company in China. Mark addresses challenges facing pharmaceutical companies, including differences between sales and marketing strategies in China versus Western markets, and discusses the overall outlook of China's evolving market. In this interview, Mark Lotter, founder and CEO of NovaMed, shares his experience transitioning from big pharma to a start-up, specialty pharmaceutical company in China. Mark addresses challenges facing pharmaceutical companies, including differences between sales and marketing strategies in China versus Western markets, and discusses the overall outlook of China's evolving market. http://www.gbipharma.com/podcast/mp3/GBI Mark Lotter Interview.mp3 Tue, 25 Sep 2007 01:21:22 +0000 33.59 Generalbiologic Generalbiologic In this interview, Arthur covers a lot of ground, hitting venture capital, private equity, and entrepreneurialism in China's healthcare and life science industries. Arthur's experience ranges across a number of deal types, from early to late stage, and public offerings. In this interview, Arthur covers a lot of ground, hitting venture capital, private equity, and entrepreneurialism in China's healthcare and life science industries. Arthur's experience ranges across a number of deal types, from early to late stage, and public offerings. http://www.gbipharma.com/podcast/mp3/GBI Arthur Mok Interview Part I.mp3 Fri, 24 Aug 2007 09:00:08 +0000 25.44 Generalbiologic Generalbiologic In this interview, Arthur covers a lot of ground, hitting venture capital, private equity, and entrepreneurialism in China's healthcare and life science industries. Arthur's experience ranges across a number of deal types, from early to late stage, and public offerings. In this interview, Arthur covers a lot of ground, hitting venture capital, private equity, and entrepreneurialism in China's healthcare and life science industries. Arthur's experience ranges across a number of deal types, from early to late stage, and public offerings. http://www.gbipharma.com/podcast/mp3/GBI Arthur Mok Interview Part II.mp3 Fri, 24 Aug 2007 09:00:08 +0000 19.28 Generalbiologic Generalbiologic In this interview, Tony expands upon China's intellectual property landscape, especially related to biotechnology and pharmaceuticals. He addresses both systematic challenges and practical considerations for multinationals, investors, and China's domestic enterprises. In this interview, Tony expands upon China's intellectual property landscape, especially related to biotechnology and pharmaceuticals. He addresses both systematic challenges and practical considerations for multinationals, investors, and China's domestic enterprises. http://www.gbipharma.com/podcast/mp3/GBI Tony Chen Interview Part I.mp3 Fri, 24 Aug 2007 09:00:08 +0000 28.50 Generalbiologic Generalbiologic In this interview, Tony expands upon China's intellectual property landscape, especially related to biotechnology and pharmaceuticals. He addresses both systematic challenges and practical considerations for multinationals, investors, and China's domestic enterprises. In this interview, Tony expands upon China's intellectual property landscape, especially related to biotechnology and pharmaceuticals. He addresses both systematic challenges and practical considerations for multinationals, investors, and China's domestic enterprises. http://www.gbipharma.com/podcast/mp3/GBI Tony Chen Interview Part II.mp3 Fri, 24 Aug 2007 09:00:08 +0000 24.19 Generalbiologic